A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated follicular non-Hodgkin's lymphoma.
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2019
At a glance
- Drugs Rituximab (Primary) ; Antineoplastics
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 19 Sep 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
- 07 Feb 2013 New trial record